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Modulation of renal superoxide dismutase by
telmisartan therapy in C57BL/6-Ins2Akita diabetic mice
Hiroki Fujita1, Hiromi Fujishima1, Tsukasa Morii1, Takuya Sakamoto2, Koga Komatsu2, Mihoko Hosoba1,
Takuma Narita1, Keiko Takahashi3, Takamune Takahashi3 and Yuichiro Yamada1
Renal superoxide excess, which is induced by an imbalance of the superoxide-producing enzyme NAD(P)H oxidase and the
superoxide-scavenging enzyme superoxide dismutase (SOD) under hyperglycemia, increases oxidative stress and contributes to
the development of diabetic nephropathy. In this study, we treated non-obese and hypoinsulinemic C57BL/6-Ins2Akita (C57BL/6-
Akita) diabetic mice with telmisartan (5mgkg 1per day), an angiotensin II type 1 receptor blocker, or amlodipine (5mgkg 1per
day), a calcium channel blocker, for 4 weeks and compared the effects of these two anti-hypertensive drugs on renal NAD(P)H
oxidase, SOD and transcription factor Nrf2 (NF-E2-related factor 2), which is known to upregulate several antioxidant enzymes
including SOD. Vehicle-treated C57BL/6-Akita mice exhibited higher renal NAD(P)H oxidase and lower renal SOD activity with
increased levels of renal superoxide than the C57BL/6-wild-type non-diabetic mice. Interestingly, telmisartan treatment not only
reduced NAD(P)H oxidase activity but also enhanced SOD activity in C57BL/6-Akita mouse kidneys, leading to a reduction of
renal superoxide levels. Furthermore, telmisartan-treated C57BL/6-Akita mice increased the renal protein expression of SOD and
Nrf2. In parallel with the reduction of renal superoxide levels, a reduction of urinary albumin levels and a normalization of
elevated glomerular ﬁltration rate were observed in telmisartan-treated C57BL/6-Akita mice. In contrast, treatment with
amlodipine failed to modulate renal NAD(P)H oxidase, SOD and Nrf2. Finally, treatment of C57BL/6-Akita mice with apocynin,
an NAD(P)H oxidase inhibitor, also increased the renal protein expression of SOD and Nrf2. Collectively, our data suggest that
NAD(P)H oxidase negatively regulates renal SOD, possibly by downregulation of Nrf2, and that telmisartan could upregulate
renal SOD by the suppression of NAD(P)H oxidase and subsequent upregulation of Nrf2, leading to the amelioration of renal
oxidative stress and diabetic renal changes.
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INTRODUCTION
Growing evidence indicates that superoxide anion (O2
  ) excess
induced by chronic hyperglycemia contributes to glomerular injury,
which characterizes diabetic nephropathy (DN) through the forma-
tion of secondary reactive oxygen species including peroxynitrite and
hydroxyl radicals.1–4 Two endogenous enzymes, NAD(P)H oxidase
and superoxide dismutase (SOD), are thought to be key determinants
for the superoxide anion levels in kidneys. NAD(P)H oxidase is the
most important source of superoxide anions,5–8 whereas SOD is a
major defender against superoxide anions.9,10 SOD consists of three
enzymatic isoforms: cytosolic CuZn-SOD (SOD1), mitochondrial
Mn-SOD (SOD2), and extracellular CuZn-SOD (SOD3).10,11 These
three isoforms are derived from distinct genes but catalyze the same
reaction.11 Each SOD isoform neutralizes superoxide anions into
hydrogen peroxide (H2O2)a n dm o l e c u l a ro x y g e n , 9,10 followed by
the reduction of hydrogen peroxide to water (H2O) by catalase in
peroxisomes or glutathione peroxidase in mitochondria.1,12 Thus,
SOD serves as a major antioxidant enzyme responsible for the ﬁrst
step of the superoxide removal system. Recent studies of streptozoto-
cin-induced diabetic rats have shown that chronic hyperglycemia
enhance NAD(P)H oxidase activity in kidneys.4,13,14 Furthermore,
we have more recently demonstrated that chronic hyperglycemia
causes a reduction of renal SOD expression and activity in a mouse
model susceptible to the development of DN.15 On the basis of these
ﬁndings, renal alterations of NAD(P)H oxidase and SOD enzymes are
likely to be responsible for the renal superoxide excess observed in
chronic hyperglycemia.
Angiotensin II is an important vasoconstrictor that regulates
systemic and glomerular hemodynamics. In addition, angiotensin II
is also known to promote sodium reabsorption, cell growth and
extracellular matrix deposition in kidneys.16 These effects are generally
triggered by signaling via angiotensin II type 1 (AT1) receptors.16
Therefore, AT1 receptor blockade not only improves systemic hyper-
tension but also could provide direct renoprotective effects. Indeed,
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www.nature.com/hrAT1 receptor blockers (ARBs) have been shown to exert greater
renoprotective effects in patients with DN than other classes of
anti-hypertensive drugs. Clinical studies have reported that irbesar-
tan, an ARB, signiﬁcantly inhibits the aggravation of renal function in
type 2 diabetic patients with overt DN compared with amlodipine,17
a calcium channel blocker, and that valsartan, another ARB, signiﬁ-
cantly reduces albuminuria in type 2 diabetic patients with incipient
DN compared with amlodipine.18 It is noteworthy that the renopro-
tective effects of ARBs were independent of their systemic blood
pressure-lowering properties. Recently, evidence for the anti-oxidative
effects of ARBs has been accumulating for several members of the
ARB class. Clinical studies have reported that ARBs, including
losartan, candesartan, olmesartan, telmisartan and valsartan, reduce
the urinary levels of oxidative stress marker 8-hydroxy-2¢-deoxygua-
nosine in patients with DN.19,20 Oxidative stress induced by super-
oxide excess under chronic hyperglycemia has been thought to be a
major factor involved in the pathogenesis of DN.21 Therefore, the
powerful renoprotective properties of ARBs may be attributed to their
antioxidative effects.
The role of angiotensin II in modulating superoxide-producing
enzyme NAD(P)H oxidase has been explored in vascular cells and
kidneys. Previous experimental studies have demonstrated that angio-
tensin II promotes superoxide generation via NAD(P)H oxidase
activation in vascular cells.22,23 Furthermore, recent experimental
studies have indicated that ARBs, such as olmesartan and telmisartan,
reduce glomerular superoxide production through downregulating the
gene expression of NAD(P)H oxidase subunits p22phox and p47phox
in subtotal nephrectomized rats24 and catalase-deﬁcient acatalasemic
mice.25 However, whether the angiotensin II signaling and its inhibi-
tion modulate the superoxide-scavenging SOD enzymes in kidneys
exposed to hyperglycemia is largely unknown.
To investigate whether AT1 receptor blockade alters the expression
and activity of SOD enzymes in kidneys exposed to hyperglycemia, we
treated non-obese and hypoinsulinemic C57BL/6-Ins2Akita (C57BL/6-
Akita) diabetic mice with telmisartan, an ARB, or amlodipine, a
calcium channel blocker, and compared the effects of these two
anti-hypertensive drugs on renal SOD. We report here that telmisartan
not only reduces renal NAD(P)H oxidase activity but also upregulates
the renal expression and activity of SOD, resulting in a reduction of
renal superoxide levels. To explore the mechanism underlying this
upregulation of renal SOD with telmisartan, we further examined
whether NAD(P)H oxidase inhibition with apocynin modulated
the renal expression of SOD and redox-sensitive transcription factor
Nrf2 (NF-E2-related factor 2), which is known to upregulate
several antioxidant enzymes, including SOD,26–28 in C57BL/6-Akita
diabetic mice.
METHODS
Experimental animals
Male C57BL/6-Akita diabetic and C57BL/6-wild-type (C57BL/6-WT) non-dia-
b e t i cm i c ew e r ep u r c h a s e df r o mS L C( S h i z u o k a ,J a p a n ) .T h em i c ew e r eh o u s e d
(n¼3–4 per cage) in a room with a relative humidity of 50% and a 12/12-h light/
dark cycle at 20–221C, and had unrestricted access to standard rodent chow and
water. Animal experiments were conducted in accordance with the Animal
Welfare Guidelines of Akita University. All procedures were approved by the
Committee on Animal Experimentation of Akita University.
Treatment protocols for telmisartan, amlodipine and apocynin
Telmisartan was kindly provided by Boehringer Ingelheim (Tokyo, Japan).
Amlodipine, apocynin (4¢-hydroxy-3¢-methoxyacetophenone) and carboxy-
methylcellulose-Na were purchased from Sigma-Aldrich (St Louis, MO, USA).
To investigate the effects of telmisartan and amlodipine on renal SOD and
NAD(P)H oxidase, 10-week-old male C57BL/6-Akita diabetic mice were
administered with telmisartan (5mgkg 1) orally or amlodipine (5mgkg 1)
dissolved in a 0.5% carboxymethylcellulose-Na solution once daily for 4 weeks.
Mice in the control group were given the same volume of 0.5% carboxy-
methylcellulose-Na solution alone as the vehicle. To examine the effects of
NAD(P)H oxidase inhibition on renal SOD, 10-week-old male C57BL/6-Akita
diabetic mice were treated with apocynin (40mgkg 1per day) for 8 weeks.
Apocynin was added in the drinking water and was administered orally to the
mice as described previously.29 Mice in the control group were given water
alone as the vehicle.
Measurement of blood and urine parameters
Blood glucose was measured using Glucocard Diameter (Arkray, Tokyo, Japan)
on samples obtained after a 6-h daytime fast. Blood urea nitrogen, total plasma
cholesterol and plasma triglycerides were enzymatically measured by an
autoanalyzer (Fuji Dry-Chem 5500, Fuji Film, Tokyo, Japan). Urinary albumin
excretion was assessed by determining the albumin-to-creatinine ratio in
morning spot urine as previously described.30 Urine albumin and creatinine
were measured by an Albuwell-M Murine Microalbuminuria ELISA kit and a
Creatinine Companion kit, respectively (Exocell, Philadelphia, PA, USA).
Measurement of physiological parameters and renal histologic
analysis
Systolic blood pressure was measured in conscious trained mice at room
temperature using a non-invasive tail cuff and a pulse transducer system
(BP-98A, Softron, Tokyo, Japan). The glomerular ﬁltration rate (GFR) was
measured by a single-bolus ﬂuorescein isothiocyanate-inulin injection method
as described previously.31 For renal histologic analysis, we stained kidney
sections with periodic acid-Schiff (PAS). We used a semi-quantitative score
to evaluate the degree and extent of glomerular mesangial expansion as
described previously.30
Renal superoxide production and activity of NAD(P)H oxidase
and SOD
Renal superoxide levels were assessed by dihydroethidium (DHE) histochem-
istry and a water-soluble tetrazolium salt (WST-1, 2-[4-iodophenyl]-3-[4-
nitrophenyl]-5-[2,4-disulfophenyl]-2H-tetrazolium) reduction assay as pre-
viously described.15 The speciﬁcity of the WST-1 assay was conﬁrmed by
pretreating 10mg of kidney tissue with polyethylene glycol-SOD (20U; Sigma-
Aldrich) overnight at 371C. Renal superoxide levels were expressed as the
absorbance at 450nm per 10mg tissue. For the DHE staining, we examined the
Eth-DNA ﬂuorescence at 480nm excitation and 610nm emission. To measure
renal NAD(P)H oxidase and SOD activity, we prepared kidney lysates using
phosphate-buffered saline-perfused and freshly removed renal cortical tissue as
previously described.15 Renal NAD(P)H oxidase activity was measured by a
lucigenin-enhanced chemiluminescence assay as previously described.14 Renal
SOD activity was determined using an SOD assay kit-WST (Dojindo Molecular
Technologies, Gaithersburg, MD, USA) as previously described.15 The protein
amount was measured using a bicinochoninic acid protein assay (Sigma-
Aldrich). The enzymatic activity of NAD(P)H and SOD were expressed in
relative chemiluminescence (light) units (RLU) per 100mg protein and units
per mg protein, respectively.
Western blot analysis and immunohistochemistry
For western blot analysis, the kidney lysate prepared for the SOD activity
measurement was used. In all, 20mg of proteinwas separated by SDS-PAGE and
subjected to immunoblots. As the primary antibody, we used rabbit anti-CuZn-
SOD (SOD1) (1:10000; Stressgen, Ann Arbor, MI, USA), anti-Mn-SOD
(SOD2) (1:10000; Stressgen), anti-EC-SOD (SOD3) (1:2000; Stressgen) or
anti-Nrf2 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) poly-
clonal antibodies. The loading of lysate protein was evaluated by an immuno-
blot using rabbit anti-actin antibody (1:1000; Sigma-Aldrich). The intensity of
the signals was semi-quantiﬁed using Adobe Photoshop (version CS4; Adobe
Systems, San Jose, CA, USA). For the immunohistochemistry, cryostat sections
were prepared as previously described.15 We labeled the sections with rabbit
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Hypertension Researchanti-CuZn-SOD (SOD1) (1:100; Stressgen), anti-Mn-SOD (SOD2) (1:100;
Stressgen) or anti-EC-SOD (SOD3) (1:50; Stressgen) polyclonal antibodies
for 1h at room temperature, followed by Alexa Fluor 488-conjugated goat
anti-rabbit IgG antibody (1:200; Molecular Probes, Eugene, OR, USA) for
30min at room temperature. We then counterstained the sections with ToPro-3
(Molecular Probes).
Measurement of renal prostaglandin E2 (PGE2) levels
Renal PGE2 levels were measured using freshly isolated renal cortical tissue as
previously described.32 The levels were expressed as the ratio of renal cortical
PGE2 to protein.
Statistical analysis
Data were presented as the mean±s.e.m. Statistical analyses were conducted
using GraphPad Prism software (GraphPad, San Diego, CA, USA). Differences
between groups were determined by an unpaired t-test or a one-way ANOVA,
followed by Bonferroni’s multiple comparison test. A Po0.05 was considered
statistically signiﬁcant.
RESULTS
Biochemical and physiological parameters, and renal
histopathology after a 4-week treatment with telmisartan
or amlodipine in C57BL/6-Akita diabetic mice
Table 1 shows the biochemical and physiological parameters after a
4-week treatment with telmisartan or amlodipine in C57BL/6-Akita
diabetic mice. Data from telmisartan-treated mice were compared
with those from the mice treated with amlodipine. Treatment with
either telmisartan or amlodipine did not affect blood glucose, body
weight, blood urea nitrogen, total cholesterol or triglyceride levels.
Compared with the vehicle-treated mice, both amlodipine-treated and
telmisartan-treated mice exhibited signiﬁcantly lower blood pressure
levels. There were no signiﬁcant differences in blood pressure levels
between amlodipine-treated and telmisartan-treated mice. Compared
with the data from vehicle-treated mice, treatment with telmisartan
signiﬁcantly reduced urinary albumin levels, GFR, and the left kidney
weight-to-body weight ratio (LKW/BW) in C57BL/6-Akita diabetic
mice, whereas treatment with amlodipine had no effect. As we recently
reported, glomerular pathological damages were relatively mild
in 10–15-week-old C57BL/6-Akita diabetic mice.15 A difference in
glomerular pathological changes evaluated using the mesangial expan-
sion score was not observed between vehicle-treated and telmisartan-
treated C57BL/6-Akita diabetic mice.
Effects of treatment with telmisartan on renal superoxide
production, NAD(P)H oxidase activity and SOD activity in
C57BL/6-Akita diabetic mice
Figure 1 shows renal superoxide production, NAD(P)H oxidase
activity and SOD activity after a 4-week treatment with telmisartan
or amlodipine in C57BL/6-Akita diabetic mice. Renal superoxide
levels were assessed by DHE histochemistry and a WST-1 assay.
The DHE ﬂuorescence signal, which reﬂects superoxide production,
was decreased in the glomeruli of telmisartan-treated C57BL/6-Akita
diabetic mice compared with vehicle-treated mice (Figure 1A).
Furthermore, telmisartan but not amlodipine signiﬁcantly reduced
renal superoxide levels as determined by the WST-1 assay in C57BL/6-
Akita diabetic mice (Figure 1B). Consistent with a recent
report,33 telmisartan reduced NAD(P)H activity in the kidneys of
C57BL/6-Akita diabetic mice close to the levels of C57BL/6-wild-type
(C57BL/6-WT) non-diabetic mice (Figure 1C). Interestingly,
telmisartan-treated C57BL/6-Akita diabetic mice but not amlodi-
pine-treated mice showed signiﬁcantly higher renal SOD activity
than the vehicle-treated mice (Figure 1D). Thus, it should be noted
that two telmisartan-treated and amlodipine-treated C57BL/6-Akita
diabetic mouse groups exhibited different levels of renal NAD(P)H
and SOD activity, despite comparable levels of hyperglycemia and
blood pressure.
Effects of treatment with telmisartan on the renal expression
of SOD isoforms and Nrf2 in C57BL/6-Akita diabetic mice
We next examined whether a 4-week treatment with telmisartan
affected the renal expression of SOD isoforms and Nrf2.
Western blot analysis revealed increased expression of the SOD
isoforms SOD1, SOD2, and SOD3 and Nrf2 in the renal cortex of
telmisartan-treated C57BL/6-Akita diabetic mice, whereas renal
SOD and Nrf2 upregulation was not observed in amlodipine-treated
mice (Figure 2). Figure 3 shows the renal SOD isoform expression
using immunoﬂuorescence histochemistry. As shown in our
recent report,15 SOD1 and SOD2 were broadly expressed in glomer-
ular and tubular cells (tubular SOD1 expression not shown). SOD3
expression was observed in glomerular capillaries and the arteriolar
wall (expression of SOD3 in the arteriolar wall not shown). Consistent
with the results of the western blot analysis, strong SOD1 and
SOD3 signals in the glomeruli and SOD2 signals in proximal tubules
were observed in telmisartan-treated C57BL/6-Akita diabetic mice.
Table 1 Physiological and biochemical parameters after 4-week treatment with amlodipine or telmisartan in C57BL/6-Akita diabetic mice
C57BL/6-WT
C57BL/6-Akita
Parameter No treatment Vehicle Amlodipine Telmisartan
n 8668
Body weight (g) 23.6±0.7 20.6±0.6* 19.9±0.4* 20.6±0.5*
Systolic blood pressure (mmHg) 99±21 1 6 ±5* 103±2z 102±3z
Blood glucose (mgdl 1)1 4 8 ±84 6 3 ±18w 429±19w 447±18w
BUN (mgdl 1)2 3 . 6 ±0.7 32.5±1.9* 33.2±1.9* 32.5±2.2*
Total cholesterol (mgdl 1)7 6 . 8 ±3.6 82.6±2.0 84.8±6.8 82.7±3.4
Triglyceride (mgdl 1)7 5 . 0 ±4.4 75.0±4.3 72.7±3.1 69.6±4.7
Urinary albumin (mg per mg creatinine) 9.4±4.8 59.2±6.7w 56.9±5.6w 28.6±3.9y
GFR (mlmin 1 per g BW) 10.0±0.5 16.3±1.1w 16.7±0.9w 12.7±0.4z
LKW/BW (gkg 1)7 . 2 ±0.3 11.5±0.4w 11.9±0.5w 9.4±0.2w,y
Mesangial expansion score 0.15±0.01 0.44±0.03w 0.41±0.05w 0.40±0.03w
Abbreviations: BUN, blood urea nitrogen; BW, body weight; GFR, glomerular ﬁltration rate; LKW, left kidney weight.
Values are means±s.e.m. *Po0.01, wPo0.001 vs. C57BL/6-WT. zPo0.05, yPo0.01 vs. vehicle.
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diabetic mice did not exhibit increased expression of SOD
isoforms.
NAD(P)H oxidase inhibition by treatment with apocynin and
renal alterations of the SOD enzyme and Nrf2 in C57BL/6-Akita
diabetic mice
We found that telmisartan reduced renal superoxide levels through
downregulating NAD(P)H oxidase and upregulating SOD in a mouse
model of diabetes, C57BL/6-Akita mice. To explore whether
NAD(P)H oxidase regulates the SOD enzyme via Nrf2 in kidneys,
we treated C57BL/6-Akita diabetic mice with apocynin, an NAD(P)H
oxidase inhibitor, for 8 weeks and investigated the renal alterations of
the SOD enzyme and Nrf2. As shown in Table 2, apocynin treatment
did not affect body weight, blood pressure, blood glucose or LKW/
BW. As expected, a marked reduction of renal superoxide and
NAD(P)H oxidase activity was observed in the apocynin-treated
C57BL/6-Akita diabetic mice. In addition, apocynin signiﬁcantly
lowered urinary albumin levels and ameliorated elevated GFR in
C57BL/6-Akita diabetic mice. Figure 4 shows the western blot analysis
of renal cortical expression of SOD isoforms and Nrf2 after an 8-week
treatment with apocynin. Interestingly, renal cortical expression levels
of SOD1, SOD2 and SOD3 isoforms and Nrf2 were signiﬁcantly
increased in apocynin-treated C57BL/6-Akita diabetic mice compared
with vehicle-treated mice.
Effects of telmisartan and apocynin on renal production
of vasodilatory PGE2 in C57BL/6-Akita diabetic mice
To elucidate the mechanism through which superoxide reduction due
to treatment with telmisartan or apocynin affects glomerular hemo-
dynamics, we measured renal cortical levels of vasodilatory PGE2,
which contributes to the development of glomerular hypertension in
C57BL/6-Akita diabetic mouse groups treated with telmisartan for 4
weeks and with apocynin for 8 weeks. As shown in Figure 5, a
reduction of renal PGE2 production was observed in the telmisar-
tan-treated and apocynin-treated groups compared with the vehicle-
treated group.
DISCUSSION
Telmisartan is a unique ARB with peroxisome proliferator-activated
receptor-g activity,34 and this ARB has been reported to offer a more
powerful antioxidative effect than other members of the ARB class in
patients with DN.20 In this study, we ﬁrst treated 10-week-old C57BL/
6-Akita diabetic mice with telmisartan for 4 weeks and investigated
whether AT1 receptor blockade by telmisartan modulated the super-
oxide-scavenging SOD enzyme in kidneys exposed to hyperglycemia.
C57BL/6-Akita mice are well-characterized as a model of non-obese
and hypoinsulinemic diabetes, and develop marked hyperglycemia as
early as 4 weeks of age because of a single mutation in cysteine 96 to
tyrosin in the insulin 2 gene (Ins2Akita).35,36 Chemicals such as
streptozotocin or alloxan are widely used to induce diabetes in
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Figure 1 Effects of telmisartan treatment on renal superoxide production, NAD(P)H oxidase activity and SOD activity in C57BL/6-Akita diabetic mice. The
C57BL/6-Akita diabetic mice were treated with the vehicle, amlodipine or telmisartan for 4 weeks. The treatment started at 10 weeks of age and ended at
14 weeks of age. The data from C57BL/6-Akita diabetic mice were compared with those from age-matched C57BL/6-wild-type non-diabetic mice.
(A) Representative glomerular DHE staining after a 4-week treatment with telmisartan. (a) C57BL/6-wild-type; (b) vehicle-treated C57BL/6-Akita; (c)
amlodipine-treated C57BL/6-Akita; (d) telmisartan-treated C57BL/6-Akita. (B) Renal superoxide production after a 4-week treatment with telmisartan. Data
are presented as the mean±s.e.m. SOD+, kidney tissue pre-incubated with SOD-PEG protein; SOD , kidney tissue without SOD-PEG protein. n¼5p e r
group. *Po0.001 vs. wild-type. +Po0.01 vs. vehicle. (C) Renal NAD(P)H oxidase activity after a 4-week treatment with telmisartan. Data are presented as
the mean±s.e.m. n¼5 per group. *Po0.001 vs. wild-type. zPo0.001 vs. vehicle. (D) Renal SOD activity after a 4-week treatment with telmisartan. Data
are presented as the mean±s.e.m. n¼5 per group. *Po0.001 vs. wild-type. zPo0.001 vs. vehicle.
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Hypertension Researchexperimental animals. However, these chemicals have been documen-
ted to generate reactive oxygen species and enhance oxidative stress.37
Therefore, the C57BL/6-Akita mouse model offers a unique oppor-
tunity to precisely assess the renal alterations of oxidative stress and its
related enzymes.
Consistent with the results of clinical studies,17,18 our data also
indicate that an ARB, telmisartan, is superior to a calcium channel
blocker, amlodipine, at producing renoprotective effects in C57BL/6-
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Figure 2 Western blot analysis of renal cortical SOD isoforms and Nrf2
expression after a 4-week treatment with the vehicle (VE), amlodipine (AM)
or telmisartan (TE) in C57BL/6-Akita diabetic mice. WT indicates non-
diabetic C57BL/6-wild-type mice. The relative intensity of the SOD-to-actin
or Nrf2-to-actin ratios to WT is also shown in the lower panels. Data are
presented as the mean±s.e.m. n¼4 per group. *Po0.001 vs.V E .
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Figure 3 Immunoﬂuorescence SOD isoform staining of kidney sections after a 4-week treatment with the vehicle, amlodipine or telmisartan in C57BL/6-
Akita diabetic mice. (a–d) SOD1; (e–h) SOD2; (i–l) SOD3; (a, e, i) C57BL/6-wild-type; (b, f, j) vehicle-treated C57BL/6-Akita; (c, g, k) amlodipine-treated
C57BL/6-Akita; (d, h, l) telmisartan-treated C57BL/6-Akita.
Table 2 Physiological and biochemical parameters after 8-week
treatment with apocynin in C57BL/6-Akita diabetic mice
Parameter Vehicle Apocynin
n 55
Body weight (g) 23.0±0.4 23.4±0.4
Systolic blood pressure (mmHg) 116±21 1 5 ±4
Blood glucose (mgdl 1)4 6 6 ±18 474±7
Urinary albumin (mg per mg creatinine) 66.4±5.8 32.7±4.6*
GFR (mlmin 1 per g BW) 16.9±0.8 12.2±0.7*
LKW/BW (gkg 1)1 0 . 3 ±0.5 9.3±0.4
Renal superoxide (A450/10mg tissue) 0.609±0.023 0.244±0.023w
Renal NAD(P)H oxidase activity
(RLU per 100mg protein)
1236±16 315±20w
Renal SOD activity (Umg 1 protein) 824±34 1285±78w
Abbreviations: BW, body weight; GFR, glomerular ﬁltration rate; LKW, left kidney weight;
RLU, relative light units; SOD, superoxide dismutase.
Values are means±s.e.m. *Po0.01, wPo0.001 vs. vehicle.
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Hypertension ResearchAkita diabetic mice. In the SMARTstudy, it was reported that changes
in the urinary albumin-to-creatinine ratio from baseline to the end of
the treatment period were  36% in type 2 diabetic and microalbu-
minuric patients treated with valsartan, an ARB, for 24 weeks
and +30% in those treated with amlodipine for 24 weeks, despite
comparable blood pressure reductions.38 These results indicate that
monotherapy with amlodipine may be insufﬁcient for albumin-
to-creatinine ratio reduction. However, the SMART study also sug-
gested that if blood pressure is sufﬁciently lowered by amlodipine
treatment, albumin-to-creatinine ratio would also be reduced to some
extent. Similar to the results of the SMART study, this study showed
that treatment with telmisartan, not amlodipine, reduced urinary
albumin levels and normalized elevated GFR that reﬂects glomerular
hypertension in C57BL/6-Akita diabetic mice, despite comparable
levels of hyperglycemia and blood pressure between the two groups
treated with these drugs. Further blood pressure reduction with
amlodipine treatment may be needed to reduce urinary albumin
and glomerular hypertension in C57BL/6-Akita diabetic mice.
In this study, we used the tail cuff method to measure blood
pressure. Our data did not indicate a difference in blood pressure
between the telmisartan-treated and amlodipine-treated C57BL/6-
Akita diabetic mice. However, the tail cuff method has several
limitations in blood pressure measurement. Therefore, measuring
blood pressure with the telemetry method may be necessary to
precisely assess the effects of anti-hypertensive drugs on reducing
blood pressure in C57BL/6-Akita diabetic mice.
Our experiments revealed the novel ﬁnding that telmisartan not
only reduced NAD(P)H oxidase activity but also enhanced SOD
activity in the kidneys of C57BL/6-Akita diabetic mice. As expected,
renal alterations of these enzymes resulted in a reduction of renal
superoxide levels. In contrast, treatment with amlodipine failed to
modulate renal NAD(P)H oxidase and SOD enzymes. The differences
in renoprotection between telmisartan and amlodipine may in part be
attributed to their ability to modulate renal NAD(P)H oxidase and
SOD enzymes. A recent experimental study reported that treatment
with low doses of telmisartan (0.1–0.3mgkg 1per day) did not affect
renal SOD activity in non-diabetic mice.25 However, our study
indicated that treatment with a high dose of telmisartan (5mgkg 1
per day) enhanced renal SOD activity in C57BL/6-Akita diabetic mice.
It is possible that high doses of this ARB are needed to enhance renal
SOD activity. Paralleling the elevation of renal SOD activity in
telmisartan-treated C57BL/6-Akita diabetic mice, our immunohisto-
chemical study revealed increases in the protein expression of SOD1
and SOD3 isoforms in glomeruli and of the SOD2 isoform in
the proximal tubules of these mice. Western blot analysis conﬁrmed
the ﬁnding that telmisartan therapy increases the protein expression
of SOD1, SOD2 and SOD3 in the kidneys of C57BL/6-Akita
diabetic mice.
As angiotensin II signaling directly promotes NAD(P)H oxidase
activation,22,23 the downregulation of renal NAD(P)H oxidase by AT1
receptor blockade is a reasonable result. However, the mechanism by
which telmisartan upregulates renal SOD remains unclear. We
hypothesized that NAD(P)H oxidase would negatively regulate the
renal expression of SOD or transcription factor Nrf2, which is known
to upregulate several antioxidant enzymes including SOD.26–28 To test
this hypothesis, we treated C57BL/6-Akita diabetic mice with an
NAD(P)H oxidase inhibitor, apocynin, for 8 weeks and investigated
the alteration of renal SOD and Nrf2 expression. As expected,
apocynin treatment markedly lowered renal NAD(P)H oxidase activity
in C57BL/6-Akita diabetic mice, resulting in the reduction of renal
superoxide levels. The reduction of renal superoxide by apocynin
therapy contributed to reducing urinary albumin levels and normal-
izing the elevated GFR in C57BL/6-Akita diabetic mice. Consistent
with the results of recent experimental studies,29,39 apocynin did not
lower the blood pressure of C57BL/6-Akita diabetic mice. Although
the cause is unclear, one possible explanation is that unlike telmisar-
tan, apocynin is not effective in blocking systemic vasoconstriction by
angiotensin II. More importantly, we found that inhibiting NAD(P)H
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Figure 4 Western blot analysis of renal cortical SOD isoform and Nrf2
expression after an 8-week treatment with the vehicle (VE) or apocynin (AP)
in C57BL/6-Akita diabetic mice. WT indicates non-diabetic C57BL/6-wild-
type mice. The relative intensity of the SOD-to-actin or Nrf2-to-actin ratios
to WT is also shown in the lower panels. Data are presented as the
mean±s.e.m. n¼4 per group. *Po0.001 vs.V E .
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Figure 5 Renal cortical PGE2 levels after a 4-week treatment with the
vehicle, amlodipine or telmisartan and after an 8-week treatment with
apocynin in C57BL/6-Akita diabetic mice. Data are presented as the
mean±s.e.m. n¼5 per group. *Po0.001.
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mice. Suppression of NAD(P)H oxidase by telmisartan also resulted in
increased expression of renal Nrf2. Taken together, our data suggest
that NAD(P)H oxidase negatively regulates renal SOD, possibly by
downregulation of Nrf2, and that telmisartan could upregulate renal
SOD by the suppression of NAD(P)H oxidase and subsequent
upregulation of Nrf2 (Figure 6).
This study does not demonstrate that other members of the ARB
class also have the ability to upregulate renal SOD. As AT1 receptor
blockade by other members of the ARB class, such as olmesartan, has
been shown to reduce renal NAD(P)H oxidase expression,24 all ARBs
may share the renal SOD upregulating effect to some extent. However,
as shown in a recent clinical study,20 there is a difference in the ability
to ameliorate oxidative stress among the ARB members. Of the
currently available ARBs, telmisartan is known to have the strongest
binding afﬁnity to AT1 receptors, the longest half-life, and a high
lipophilicity.40,41 In addition, telmisartan also acts as a partial agonist
of peroxisome proliferator-activated receptor-g.A ne x p e r i m e n t a l
study of obese and hypertensive rats has indicated that peroxisome
proliferator-activated receptor-g activation by pioglitazone therapy
downregulates NAD(P)H oxidase.42 These properties may explain the
more powerful antioxidative and renoprotective effects of telmisartan
by modulation of renal NAD(P)H oxidase and SOD.
Reactive oxygen species, including superoxide anions, induce over-
production of vasodilatory PGE2 through cyclooxygenase-2 upregula-
tion.43 PGE2 is a vasodilator for afferent arterioles, and excessive PGE2
could cause the glomerular hypertension observed in early dia-
betes.44,45 Therefore, it is thought that the reduction of renal super-
oxide with apocynin normalized elevated GFR in C57BL/6-Akita
diabetic mice. In addition, renal superoxide reductionwith telmisartan
is likely to affect glomerular pressure reduction. This study revealed
that treatment with apocynin or telmisartan reduces renal PGE2
production in C57BL/6-Akita diabetic mice. Furthermore, the ability
of telmisartan to dilate efferent arterioles through AT1 receptor
blockade also contributes to the amelioration of glomerular hyperten-
sion. Thus, renal superoxide reduction is thought to provide beneﬁcial
effects in improving abnormalities in glomerular hemodynamics in
early diabetes.
In conclusion, we report a novel ﬁnding that AT1 receptor blockade
by telmisartan treatment could upregulate renal SOD enzyme by the
suppression of NAD(P)H oxidase and subsequent upregulation of
Nrf2, leading to an improvement of oxidative stress in kidneys
exposed to hyperglycemia. These effects are expected to greatly
contribute to the amelioration of earlier diabetic renal change
observed in C57BL/6-Akita diabetic mice.
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